VRCA compared with ANIK: revenue, margins and what each company keeps, and the suppliers and customers both name

VRCAVerrica Pharmaceuticals Inc.

Mkt capRevenueRevenue

ANIKAnika Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

VRCAVerrica Pharmaceuticals Inc.

ANIKAnika Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

VRCA1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−5.22%—

ANIK

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±24.0%▲+6.73%×0.28

Q1 FY26±10.9%▼−18.81%×1.72

= impliedVRCA realized, solidANIK realized, hatchedOne scale, both sides: full bar = 48%× = |realized| ÷ impliedSource: market data

Feb 26 '26

±26.8%

▲+16.91%

×0.63

Jan 9 '26±47.6%▼−0.31%×0.01

VRCAVerrica Pharmaceuticals Inc.

3.27▼−2.39%

Mkt cap$55.1MRevenue$6MQ2 FY26Revenue$36MFY25

ANIKAnika Therapeutics, Inc.

19.22▼−0.96%

Regular sessionNov 3 '26

Mkt cap$259.8MRevenue$33MQ2 FY26Revenue$113MFY25

Compare

Regular sessionNov 3 '26

VRCAVerrica Pharmaceuticals Inc.

ANIKAnika Therapeutics, Inc.

3.27▼−2.39%

Price

19.22▼−0.96%

$55.1M

Mkt cap

$259.8M

Q2 FY26$6M

Revenue

$33MQ2 FY26

FY25$36M

Revenue

$113MFY25

VRCA3.27▼−2.39%vsANIK19.22▼−0.96%Regular sessionNov 3 '26